CLINICAL REVIEWSRapid Review Nonsteroidal Anti-inflammatory Agents and Aminosalicylates in COVID-19 InfectionsEhrenpreis, Eli D. MD; Kruchko, David H. DOAuthor Information Department of Medicine, Advocate Lutheran General Hospital, Chicago, IL The authors declare that they have nothing to disclose. Address correspondence to: David H. Kruchko, DO, 1775 Dempster Street, Park Ridge, IL 60068 (e-mail: firstname.lastname@example.org). Journal of Clinical Gastroenterology: August 2020 - Volume 54 - Issue 7 - p 602-605 doi: 10.1097/MCG.0000000000001371 Buy Metrics Abstract In the current COVID-19 pandemic, there has been concern regarding the use of ibuprofen and other nonsteroidal anti-inflammatory agents by COVID-19 infected patients. Aminosalicylates (5-ASAs) are structurally similar and have anti-inflammatory functions that resemble those of nonsteroidal anti-inflammatory agents. Since 5-ASAs are a mainstay treatment for inflammatory bowel disease, the authors review the pharmacology of both classes of drugs and discuss the potential relevance of 5-ASAs in the ongoing discussion of medication use in patients infected with COVID-19. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.